Logistic regression analysis on the use of feedback reports.

<p>Logistic regression analysis on the use of feedback reports.</p

Descriptive statistics on all relevant variables from surveys in 2009, 2010, 2011 and in total.

<p>Descriptive statistics on all relevant variables from surveys in 2009, 2010, 2011 and in total.</p

Phi correlation between <i>reasons to participate</i> and <i>the use of feedback reports</i>.

<p>Phi correlation between <i>reasons to participate</i> and <i>the use of feedback reports</i>.</p

Quality test of methodology of the included systematic reviews based on the critical appraisal sheets of the Centre of Evidence Based Medicine.

<p>Quality test of methodology of the included systematic reviews based on the critical appraisal sheets of the Centre of Evidence Based Medicine.</p

Flow diagram literature search adverse effects of breast cancer treatment.

<p>Flow diagram literature search adverse effects of breast cancer treatment.</p

Quality test of methodology of the included studies based on the critical appraisal sheets of the Centre of Evidence Based Medicine.

<p>CCS-Case-Control Study; CCT, Clinical Controlled Trial ; CI, confidential interval; CoS, cohort study; CSS, Cross Sectional Study; RCT, Randomized Controlled Trial.</p

Adverse treatment effects in relation to impairments in upper extremities and thorax.

<p><u>Intervention</u>: ALND, axillary lymph node dissection; CEF, cyclophosphamide, epirubicin and fluorouracil; CE+T, cyclophosphamide, epirubicin + docetaxel; CT, chemotherapy; HT, hormonal therapy; LN, lymph node; MRM, modified radical mastectomy; RM, radical mastectomy; RT, radiotherapy; SC, supraclavicular; SNB, sentinel node biopsy; vs., versus.</p><p><u>Outcomes</u>: CTS, carpal tunnel syndrome; HR, hazard ratio; MSD, musculoskeletal disorder OR, odds ratio; RR, relative risk; ZOL, zoledronic acids; *, data extracted from included studies.</p

Outcome of the studies regarding breast cancer treatment and adverse effects.

<p><u>Study design</u>: CCT, clinical controlled trial; Cos, cohort study; CSS, cross sectional study; pts, patients; RCT, randomized controlled trial; SR, systematic review.</p><p>Intervention: ALND, axillary lymph node dissection; art, article; CE, cyclophosphamide, epirubicin; CEF, cyclophosphamide, epirubicin and fluorouracil; CT, chemotherapy; FU, follow up; Gy, Grey; HT, hormonal therapy; IMB, internal mammarial boost; IM-MS, internal mammary and medial supraclavicular lymph node chain; IORT, intra operative radiotherapy; LRRT, locoregional radiotherapy corresponding to periclavicular, axillary level 3, and for right-side breast cancers, the internal mammary nodes; LN, lymph node; M, metastasis; N, nodal status; PAB, posterior axillary boost; RT, radiotherapy; SC, supra scapular; SNB, sentinel node biopsy; T, docetaxel; T, tumor; TAM, tamoxifen; vs., versus; wks, weeks; ZOL, Zoledronic Acid.</p><p><u>Measurement instruments</u>: BIS, bio impedance spectroscopy; BMI, body mass index; BSI, Brief Symptom Inventory; CPAQ, Chronic Pain Acceptance Questionnaire; CES-D, center for epidemiologic studies – depression scale; CTCAE, Common Terminology Criteria for Adverse Events ; DASH, disabilities of arm, shoulder and hand; EORTC-QLQ-C30-BR23, European organization for research and treatment of cancer – quality of life questionnaire- breast; FACT-G-B, functional assessment of cancer therapy – general – breast; FLIC, Functional living index – cancer; FQ, fatigue questionnaire; FPACQ, Flemish Physical Activity Computerized Questionnaire; GCQ, general coping questionnaire; HADS, hospital anxiety and depression scale; ICD, international classification of diseases; IOC, impact of cancer scale; KAPS, Kwan’s arm problem scale; LANSS, Leeds Assessment of Neuropathic Symptoms and Signs; LBCQ, lymphedema breast cancer questionnaire; LEFT-BC, Lymphedema Evaluation Following Treatment for Breast Cancer; LENT-SOMA, late effects normal tissue – subjective objective management analytic; Li-Sat, life satisfaction; MASS, measure of arm symptoms survey; MET, metabolic equivalent ; MOS, medical outcomes study; MPQ, McGill pain questionnaire; MRC-scale, medical research council scale; MSPQ, Modified Somatic Perception Questionnaire; NPRS, numeric pain rating scale; PAISSR, Psychological Adjustment to Illness Scale-Self-Report; PAQ, physical activity questionnaire; PSI-B, Problem solving inventory-brief; ROM, range of motion; SF-36, short form-36; SPADI, shoulder pain and disability index; ULDQ, upper limb disability questionnaire; v, version; VAS, visual analogue scale; WHR, Waist-Hip ratio.</p><p><u>Outcomes</u>: ADL, activities in daily living; AWS, axillary web syndrome; CHF, cardiac heart failure; CTS, carpal tunnel syndrome; HR, Hazard Ratio; LE, lymphedema; LVEF, left ventricular ejection fraction; ns, non-significant; OR, odds ratio; MPS, myofascial pain syndrome; MSD, musculoskeletal disorders; PA, physical activity; PMPS, Post Mastectomy Pain Syndrome; RR, relative risk; sign, significant; *, data extracted from included studies.</p

Search string adverse effects.

<p>Search string adverse effects.</p

Narrative exposure therapy for posttraumatic stress disorder associated with repeated interpersonal trauma in patients with severe mental illness: a mixed methods design

In the Netherlands, most patients with severe mental illness (SMI) receive flexible assertive community treatment (FACT) provided by multidisciplinary community mental health teams. SMI patients with comorbid posttraumatic stress disorder (PTSD) are sometimes offered evidence-based trauma-focused treatment like eye movement desensitization reprocessing or prolonged exposure. There is a large amount of evidence for the effectiveness of narrative exposure therapy (NET) within various vulnerable patient groups with repeated interpersonal trauma. Some FACT-teams provide NET for patients with comorbid PTSD, which is promising, but has not been specifically studied in SMI patients. The primary aim is to evaluate NET in SMI patients with comorbid PTSD associated with repeated interpersonal trauma to get insight into whether (1) PTSD and dissociative symptoms changes and (2) changes occur in the present SMI symptoms, care needs, quality of life, global functioning, and care consumption. The second aim is to gain insight into patients’ experiences with NET and to identify influencing factors on treatment results. This study will have a mixed methods convergent design consisting of quantitative repeated measures and qualitative semi-structured in-depth interviews based on Grounded Theory. The study population will include adult SMI outpatients (n=25) with comorbid PTSD and receiving NET. The quantitative study parameters will be existence and severity of PTSD, dissociative, and SMI symptoms; care needs; quality of life; global functioning; and care consumption. In a longitudinal analysis, outcomes will be analyzed using mixed models to estimate the difference in means between baseline and repeated measurements. The qualitative study parameters will be experiences with NET and perceived factors for success or failure. Integration of quantitative and qualitative results will be focused on interpreting how qualitative results enhance the understanding of quantitative outcomes. The results of this study will provide more insight into influencing factors for clinical changes in this population. Nearly 50% of severely mentally ill (SMI) patients have been exposed to repeated violence and 30% is suffering from PTSD. Narrative exposure therapy (NET) is designed for PTSD related to repeated trauma and proved effective in refugees and other vulnerable patient groups. NET is provided to SMI patients with PTSD and the first clinical outcomes are promising. This study will analyze symptom changes after NET in relation to patients’ experiences with this treatment.</p